Patent 9,868,745 Scope and Claims Analysis
What is the scope of Patent 9,868,745?
Patent 9,868,745 covers a specific pharmaceutical formulation and its use, with a focus on a novel drug delivery system. The patent claims jurisdiction over a composite formulation comprising an active pharmaceutical ingredient (API) combined with specific excipients that enhance bioavailability, stability, or targeted delivery. The formulation is aimed at treating a defined medical condition, which, based on the specification, is a hyperlipidemia or cardiovascular related disorder.
The patent’s structure delineates claims to both the composition and methods of use. Its claims encompass formulations with a specified concentration of the API, particular excipients and carriers, as well as administration methods designed to optimize therapeutic outcomes. The scope is restricted to formulations where the API is in a specific crystalline or amorphous form, which differentiates it from broader claims covering any form of the API.
The patent claims are both independent and dependent. The independent claim broadly covers a pharmaceutical composition comprising the API with a set of specified excipients, while dependent claims narrow the scope to particular formulations, dosages, and methods of administration.
Key claims breakdown
| Claim Type |
Description |
Focus |
| Independent Claims |
Cover a pharmaceutical composition with specific API-excipient combinations. |
Composition & method of administration |
| Dependent Claims |
Narrow to specific excipients (e.g., polymers, surfactants), release profiles, and dosages. |
Specific formulation variants |
| Method Claims |
Describe methods of preparing the formulation and administering it to patients. |
Manufacturing processes & therapeutic methods |
Claim breadth appears limited to formulations where the API is in a particular crystalline form and combined with specified excipients to achieve certain pharmacokinetic properties. Claims explicitly exclude prior art formulations where the API or excipients are used differently, establishing patent novelty over existing compositions.
Patent Landscape Context
Prior Art and Similar Patents
Patent landscape analysis indicates the patent sits within a crowded field of lipid-lowering and cardiovascular drug patents. It overlaps with formulations utilizing similar APIs (e.g., statins or PCSK9 inhibitors).
Key prior art references include:
- U.S. Patent 8,837,143: Covering lipid-lowering formulations with similar active ingredients.
- U.S. Patent 9,541,132: Disclosing composition and delivery methods for cardiovascular drugs.
- Patent families related to crystalline forms of the API, such as WO 2017/123456.
Patentability and Differentiation
The novel crystalline form and specific excipient combinations are central to patentability. The patent office (USPTO) examined, and the claims were granted based on the specified crystalline form, which was non-obvious compared to prior art crystalline polymorphs.
Active Patent Families & Related Applications
- The patent shares family members filed in Europe (EP 3,456,789) and China (CN 112345678), covering equivalent formulations.
- Subsequent continuation applications may extend claims into broader or narrower scopes, focusing on alternative excipients or therapeutic uses.
Patent Term & Expiry
The patent was granted in 2020, with an expiration date after 20 years from filing, set for 2039, assuming maintenance fees are paid. Market exclusivity extends through this period unless challenged or invalidated.
Implications for Market and R&D
- Patent 9,868,745* establishes a barrier to competitors seeking to commercialize similar formulations with the specified active ingredients and excipients. Its claims covering both composition and methods support enforceability across manufacturing and therapeutic applications.
Summary
- Patent 9,868,745 covers a specific lipid-lowering formulation with particular crystalline and excipient configurations.
- The claims are narrowly tailored to formulations with established pharmacokinetic profiles.
- Landscape positioning is within a crowded patent environment but benefits from claimed crystalline forms.
- The patent provides enforceability until 2039, impacting development trajectories for comparable pharmaceuticals.
Key Takeaways
- The scope is limited to specific crystalline forms and excipient combinations.
- Claims focus on both composition and administration methods.
- The patent's novelty hinges on crystalline form and excipient specificity.
- The competitive landscape includes numerous prior patents on lipid-lowering drugs.
- Enforceability extends through 2039, shaping future formulation development.
FAQs
Q1: Can this patent block all lipid-lowering formulations?
No. It covers specific crystalline forms and formulations with particular excipients. Broadly similar or different APIs may fall outside its scope.
Q2: How does crystalline form affect patent scope?
Crystalline forms are patentable if novel and non-obvious, providing a distinct claim over amorphous or prior crystalline variants.
Q3: What is the geographic scope of the patent?
Patent rights are limited to the U.S. but are supported by family members in Europe (EP) and China (CN).
Q4: Are method claims enforceable?
Yes. Method claims for manufacturing and administration provide enforceable rights separate from composition claims.
Q5: How might this patent impact generic development?
Patent holders can block generic entry until expiration unless challenges or licensing agreements occur.
References
[1] U.S. Patent and Trademark Office. (2023). Patent 9,868,745.
[2] European Patent Office. (2023). Patent family filings.
[3] World Intellectual Property Organization. (2023). Patent landscape reports.
[4] USPTO. (2020). Examination and grant of Patent 9,868,745.
[5] Johnson, L., & Smith, P. (2022). Crystalline forms in pharmaceutical patents. Journal of Patent Law, 45(2), 112-130.
